Navigation Links
Watson Announces Favorable District Court Ruling in Generic Mucinex® Patent Suit
Date:2/9/2011

MORRISTOWN, N.J., Feb. 9, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that the United States District Court for the Southern District of Florida has ruled that Watson's generic versions of Mucinex®, Mucinex® D and Mucinex® DM (Guaifenesin, Dextromethorphan HBr/ Guaifenesin, and Pseudoephedrine/Guaifenesin) Extended-Release products, do not infringe U.S. Patent No. 6,372,252 (the "'252 Patent").

The Company said it is continuing to seek final FDA approval of the products.

In 2009, Reckitt Benckiser sued Watson Laboratories, Inc. for patent infringement related to the generic versions of Mucinex®.  The Mucinex® products had total U.S. sales of approximately $500 million for the twelve months ending December 31, 2010, according to IMS Health and IRI and are indicated to help loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive.  

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing and outcome of the pending patent litigation; the difficulty of predicting the timing and outcome of any appeal of the pending patent litigation; the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31,2009 and Watson's quarterly report on Form 10-Q for the period ended September 30, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Mucinex® is a registered trademark of Reckitt Benckiser, Inc.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)CONTACTS:Investors:Patty Eisenhaur(973) 355-8141Media:Charlie Mayr(973) 355-8483
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2010 Earnings
2. Watson Confirms Welchol® Oral Suspension Patent Challenge
3. Watson Presents Outlook for Continued Long Term Growth
4. Reportlinker Adds Watson Pharmaceuticals Inc.: PharmaVitae Profile
5. Watson Announces Preliminary Financial Performance for FY 2010
6. Watson to Host Investor Day on January 21 in New York City
7. Watsons Generic Fentora® Receives FDA Approval
8. Watson to Present at the 29th Annual JP Morgan Healthcare Conference
9. Watson Announces Novel Oral Contraceptive Approval
10. Watson and Richter Announce Exclusive License Agreement for Esmya™
11. Watson Confirms Exalgo™ Patent Challenge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
(Date:9/5/2017)... Inc. has announced another milestone in their continued growth and success of the ... demands of customer engagements regionally.  ... office is located at 318 West Adams Street, Suite 1528, Chicago, IL ... Xyntek's recently opened Midwest office ... In addition ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months ... Insight is pleased to announce the appointment of three ... Tammy Wynne , Dominic Jones-Phillips and ... industry. Tammy ... team of market access writers. She has over ten ...
Breaking Medicine Technology:
(Date:9/19/2017)... , ... September 19, 2017 ... ... DACVIM, a board-certified veterinary oncologist, has agreed to serve as strategic adviser ... Dr. Tripp is founder of the Bridge Animal Referral Center (BARC) ...
(Date:9/19/2017)... Glen Cove, New York (PRWEB) , ... September 19, 2017 , ... ... that its dentist, Dr. Andrew Sami, was recently named one of the best dentists ... the leading lifestyle magazine for dental professionals nationwide. Every fall, the magazine features the ...
(Date:9/19/2017)... ... 2017 , ... When it comes to household safety, there are few priorities ... to keep babies and toddlers safe, and there's no better time for companies to ... to Check Labels, Brands that sell all kinds of common consumer products should spend ...
(Date:9/19/2017)... ... September 19, 2017 , ... Emergency ... the Certified Emergency Nurse (CEN®) certification according to a large-scale study ... of certification study, conducted by the Human Resources Research Organization (HumRRO) in late ...
(Date:9/18/2017)... (PRWEB) , ... September 19, 2017 , ... Sarantos ... Fiction Fantasy Book This December , Sarantos is proud to be the 1st (and ... off every new song release. A new song, music video, book chapter and behind ...
Breaking Medicine News(10 mins):